Gian Andri Thun

Dr. Gian Andri Thun

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LSLifeLines Cohort Study
LifeLines Cohort Study
AKAnna Köttgen
Anna Köttgen
CCCARDIoGRAM Consortium
CARDIoGRAM Consortium
DCDIAGRAM Consortium
DIAGRAM Consortium
ICICBP Consortium
ICBP Consortium
CGChristian Gieger
Christian Gieger

21 January 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPCristian Pattaro
Cristian Pattaro
ATAlexander Teumer
Alexander Teumer
MGMathias Gorski
Mathias Gorski
ACAudrey Y Chu
Audrey Y Chu
MLMan Li
Man Li
CFCaroline S Fox
Caroline S Fox
Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways.

29 March 2012 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CPCristian Pattaro
Cristian Pattaro
AKAnna Köttgen
Anna Köttgen
ATAlexander Teumer
Alexander Teumer
MGMaija Garnaas
Maija Garnaas
CBCarsten A. Böger
Carsten A. Böger
CFCaroline S. Fox
Caroline S. Fox
Chronic kidney disease (CKD) is an important public health problem with a genetic component. We performed genome-wide association studies in up to 130,600 European ancestry participants overall, and stratified for key CKD risk factors. We uncovered 6 new loci in association with estimated glomerular filtration rate (eGFR), the primary clinical measure of CKD, in or near MPPED2, DDX1, SLC47A1, CDK12, CASP9, and INO80. Morpholino knockdown of mpped2 and casp9 in zebrafish embryos revealed podocyte and tubular abnormalities with altered dextran clearance, suggesting a role for these genes in renal function. By providing new insights into genes that regulate renal function, these results could further our understanding of the pathogenesis of CKD. Chronic kidney disease (CKD) is an important public health problem with a hereditary component. We performed a new genome-wide association study in up to 130,600 European ancestry individuals to identify genes that may influence kidney function, specifically genes that may influence kidney function differently depending on sex, age, hypertension, and diabetes status of individuals. We uncovered 6 new loci associated with estimated glomerular filtration rate (eGFR), the primary measure of renal function, in or near MPPED2, DDX1, SLC47A1, CDK12, CASP9, and INO80. CDK12 effect was stronger in younger and absent in older individuals. MPPED2, DDX1, SLC47A1, and CDK12 loci were associated with eGFR in African ancestry samples as well, highlighting the cross-ethnicity validity of our findings. Using the zebrafish model, we performed morpholino knockdown of mpped2 and casp9 in zebrafish embryos and revealed podocyte and tubular abnormalities with altered dextran clearance, suggesting a role for these genes in renal function. These results further our understanding of the pathogenesis of CKD and provide insights into potential novel mechanisms of disease.

16 March 2012 in Thorax
Verified
Journal Article
Open access
PDF file
IFIlaria Ferrarotti
Ilaria Ferrarotti
GTGian Andri Thun
Gian Andri Thun
MZMichele Zorzetto
Michele Zorzetto
SOStefania Ottaviani
Stefania Ottaviani
MIMedea Imboden
Medea Imboden
MLMaurizio Luisetti
Maurizio Luisetti
Rationale α1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels. Objective This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population. Methods The authors correlated mean AAT serum levels with the main SERPINA1 variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort. Results The following ranges (5th–95th percentile) of AAT were found in the serum (g/litre): 1.050–1.640 for PI*MM, 0.880–1.369 for PI*MS, 0.730–1.060 for PI*SS, 0.660–0.997 for PI*MZ and 0.490–0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ). Conclusion This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based ‘protective threshold’ of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.

1 May 2012 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MIMedea Imboden
Medea Imboden
EBEmmanuelle Bouzigon
Emmanuelle Bouzigon
ICIvan Curjuric
Ivan Curjuric
ARAdaikalavan Ramasamy
Adaikalavan Ramasamy
AKAshish Kumar
Ashish Kumar
NPNicole Nicole Probst-Hensch
Nicole Nicole Probst-Hensch

10 September 2019 in Allergy
Verified
Journal Article
Open access
PDF file
LGLeena George
Leena George
ATAdam R. Taylor
Adam R. Taylor
AEAnna Esteve-Codina
Anna Esteve-Codina
MAMaría Soler Artigas
María Soler Artigas
GTGian Andri Thun
Gian Andri Thun
TTthe U‐BIOPRED and the EvA study teams
the U‐BIOPRED and the EvA study teams
Background: Whether the clinical or pathophysiologic significance of the “treatable trait” high blood eosinophil count in COPD is the same as for asthma remains controversial. We sought to determine the relationship between the blood eosinophil count, clinical characteristics and gene expression from bronchial brushings in COPD and asthma.Methods: Subjects were recruited into a COPD (emphysema versus airway disease [EvA]) or asthma cohort (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes, U‐BIOPRED). We determined gene expression using RNAseq in EvA (n = 283) and Affymetrix microarrays in U‐BIOPRED (n = 85). We ran linear regression analysis of the bronchial brushings transcriptional signal versus blood eosinophil counts as well as differential expression using a blood eosinophil > 200 cells/μL as a cut‐off. The false discovery rate was controlled at 1% (with continuous values) and 5% (with dichotomized values).Results: There were no differences in age, gender, lung function, exercise capacity and quantitative computed tomography between eosinophilic versus noneosinophilic COPD cases. Total serum IgE was increased in eosinophilic asthma and COPD. In EvA, there were 12 genes with a statistically significant positive association with the linear blood eosinophil count, whereas in U‐BIOPRED, 1197 genes showed significant associations (266 positive and 931 negative). The transcriptome showed little overlap between genes and pathways associated with blood eosinophil counts in asthma versus COPD. Only CST1 was common to eosinophilic asthma and COPD and was replicated in independent cohorts.Conclusion: Despite shared “treatable traits” between asthma and COPD, the molecular mechanisms underlying these clinical entities are predominately different.